Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $1.9 million.

  • Denali Therapeutics' Change in Accured Expenses fell 92.32% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$975,000, marking a year-over-year decrease of 104.78%. This contributed to the annual value of $17.4 million for FY2024, which is 556.23% up from last year.
  • As of Q3 2025, Denali Therapeutics' Change in Accured Expenses stood at $1.9 million, which was up 124.62% from -$7.7 million recorded in Q2 2025.
  • Denali Therapeutics' Change in Accured Expenses' 5-year high stood at $24.6 million during Q3 2024, with a 5-year trough of -$32.2 million in Q2 2023.
  • Its 3-year average for Change in Accured Expenses is $705,727, with a median of $1.9 million in 2025.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 649.17% in 2023, then soared by 3,249.59% in 2024.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Change in Accured Expenses stood at $7.8 million in 2021, then slumped by 48.16% to $4.0 million in 2022, then skyrocketed by 255.43% to $14.3 million in 2023, then fell by 21.14% to $11.3 million in 2024, then slumped by 92.32% to $1.9 million in 2025.
  • Its Change in Accured Expenses was $1.9 million in Q3 2025, compared to -$7.7 million in Q2 2025 and -$6.5 million in Q1 2025.